Russell Investments Group, Ltd. Sage Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

$70.2 Billion
Q1 2025

A detailed history of Russell Investments Group, Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 52,184 shares of SAGE stock, worth $340,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,184

Previous 75,740 31.1%

Holding current value

$340,761

Previous $411,000 0.73%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$5.55 - $8.66 $130,735 - $203,994	-23,556 Reduced 31.1%	52,184 $414,000
Q4 2024 Feb 13, 2025	SELL	$4.78 - $8.57 $135,646 - $243,199	-28,378 Reduced 27.26%	75,740 $411,000
Q3 2024 Nov 13, 2024	SELL	$7.02 - $13.08 $85,756 - $159,785	-12,216 Reduced 10.5%	104,118 $750,000
Q2 2024 Aug 08, 2024	BUY	$10.58 - $17.9 $792,886 - $1.34 Million	74,942 Added 181.05%	116,334 $1.26 Million
Q1 2024 May 08, 2024	SELL	$18.62 - $26.95 $349,087 - $505,258	-18,748 Reduced 31.17%	41,392 $775,000
Q4 2023 Feb 05, 2024	BUY	$17.1 - $22.26 $629,741 - $819,769	36,827 Added 157.97%	60,140 $1.3 Million
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $378,533 - $1.11 Million	22,599 Added 3165.13%	23,313 $479,000
Q2 2023 Aug 10, 2023	BUY	$40.65 - $59.54 $813 - $1,190	20 Added 2.88%	714 $33,000
Q1 2023 May 09, 2023	BUY	$37.27 - $46.57 $3,093 - $3,865	83 Added 13.58%	694 $29,000
Q2 2022 Jul 29, 2022	SELL	$27.52 - $37.99 $855,982 - $1.18 Million	-31,104 Reduced 98.07%	611 $19,000
Q1 2022 May 05, 2022	SELL	$30.71 - $45.71 $1.64 Million - $2.44 Million	-53,389 Reduced 62.73%	31,715 $1.05 Million
Q4 2021 Jan 21, 2022	SELL	$37.06 - $47.11 $99,802 - $126,867	-2,693 Reduced 3.07%	85,104 $3.63 Million
Q3 2021 Nov 08, 2021	BUY	$40.26 - $57.37 $1.86 Million - $2.65 Million	46,259 Added 111.37%	87,797 $3.89 Million
Q2 2021 Aug 04, 2021	SELL	$54.88 - $79.29 $157,340 - $227,324	-2,867 Reduced 6.46%	41,538 $2.35 Million
Q1 2021 May 10, 2021	SELL	$70.65 - $96.76 $4.27 Million - $5.85 Million	-60,443 Reduced 57.65%	44,405 $3.31 Million
Q4 2020 Feb 08, 2021	BUY	$58.41 - $89.06 $1,985 - $3,028	34 Added 0.03%	104,848 $9.09 Million
Q3 2020 Nov 09, 2020	BUY	$41.13 - $62.45 $406,981 - $617,942	9,895 Added 10.42%	104,814 $6.39 Million
Q2 2020 Aug 05, 2020	BUY	$25.95 - $43.15 $1.51 Million - $2.51 Million	58,268 Added 158.98%	94,919 $3.95 Million
Q1 2020 May 06, 2020	BUY	$26.15 - $77.24 $871,161 - $2.57 Million	33,314 Added 998.32%	36,651 $1.06 Million
Q4 2019 Jan 29, 2020	SELL	$60.18 - $154.77 $95,084 - $244,536	-1,580 Reduced 32.13%	3,337 $240,000
Q3 2019 Nov 01, 2019	BUY	$140.29 - $189.96 $382,430 - $517,830	2,726 Added 124.42%	4,917 $690,000
Q2 2019 Aug 09, 2019	SELL	$157.85 - $183.09 $16,732 - $19,407	-106 Reduced 4.61%	2,191 $401,000
Q1 2019 May 13, 2019	SELL	$89.33 - $163.65 $17 Million - $31.1 Million	-190,067 Reduced 98.81%	2,297 $365,000
Q4 2018 Feb 11, 2019	SELL	$81.94 - $139.71 $111,930 - $190,843	-1,366 Reduced 0.71%	192,364 $18.3 Million
Q3 2018 Oct 26, 2018	BUY	$138.11 - $169.04 $9.8 Million - $12 Million	70,962 Added 57.8%	193,730 $27.3 Million
Q2 2018 Aug 08, 2018	BUY	$140.36 - $175.76 $4.03 Million - $5.04 Million	28,677 Added 30.48%	122,768 $19.1 Million
Q1 2018 May 11, 2018	SELL	$152.15 - $192.33 $1.66 Million - $2.1 Million	-10,912 Reduced 10.39%	94,091 $15.2 Million
Q4 2017 Feb 06, 2018	BUY	$60.72 - $167.34 $4.4 Million - $12.1 Million	72,473 Added 222.79%	105,003 $17.5 Million
Q3 2017 Nov 07, 2017	BUY	$61.4 - $88.52 $2 Million - $2.88 Million	32,530	32,530 $2.03 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

49.9M

Call Options Held

220K

Put Options Held

312K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $388M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Sage Therapeutics, Inc. Transaction History